Dec 20 (Reuters) - Galectin Therapeutics Inc GALT.O:
BELAPECTIN WELL TOLERATED WITH NO SAFETY SIGNALS
BELAPECTIN DID NOT ACHIEVE STATISTICAL SIGNIFICANCE IN INTENT-TO-TREAT POPULATION
BELAPECTIN SHOWS SIGNIFICANT REDUCTION IN ESOPHAGEAL VARICES IN 2MG/KG COHORT
Source text: [ID:n0001140361-24-050005]
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.